Investors have a compelling, low-risk, specialty pharmaceutical company under their noses they may not know about. Capital Ideas Media president and publisher Mark Bunting sits down with Ken d’Entremont, CEO of Medexus Pharmaceuticals (TSXV:MDP), to find out about the company’s model of licensing existing drugs, its fast-growing revenue and operating profit, and how close the firm is to making a transformational deal using its $27 million in cash. PLEASE SIGN UP FOR OUR FREE DAILY EMAIL, “THE MORNING NEED TO KNOW” TO HELP GET YOU READY FOR YOUR INVESTMENT DAY CAPITALIDEASMEDIA.COM FULL DISCLOSURE: NOTHING ON THIS SITE SHOULD EVER BE CONSIDERED TO BE ADVICE, RESEARCH ORRead More →

Capital Ideas Media publisher Mark Bunting sits down with George Robinson, CEO of RavenQuest BioMed (CSE:RQB), and a thought leader in the sector. Robinson pulls the curtain back on the company’s unique technology, production growth, revenue and profitability projections, EU play, and First Nations and McGill University partnerships. RavenQuest BioMed has been building out and proving out for the last year, is now ready for prime time, and investors are waking up to the story. PLEASE SIGN UP FOR OUR FREE DAILY EMAIL, “THE MORNING NEED TO KNOW” TO HELP GET YOU READY FOR YOUR INVESTMENT DAY CAPITALIDEASMEDIA.COM FULL DISCLOSURE: NOTHING ON THIS SITE SHOULD EVERRead More →

Capital Ideas Media publisher Mark Bunting talks to Halo Labs’ (NEO:HALO;OTC:AGEEF) Founder, CEO, and Director Kiran Sidhu about how the company has become one of the fastest-growing firms in its sector in the U.S. Sidhu outlines Halo’s expansion in California and Nevada, it’s improving business in Oregon, a strategic deal in Lesotho, gives financial projections, and explains why the stock is undervalued compared to peers. PLEASE SIGN UP FOR OUR FREE DAILY EMAIL, “THE MORNING NEED TO KNOW” TO HELP GET YOU READY FOR YOUR INVESTMENT DAY CAPITALIDEASMEDIA.COM FULL DISCLOSURE: NOTHING ON THIS SITE SHOULD EVER BE CONSIDERED TO BE ADVICE, RESEARCH OR AN INVITATION TORead More →

Mark Bunting, president and publisher of Capital Ideas Media, sits down with Aras Azadian, CEO, Chairman and Co-Founder of newly-public Avicanna (TSX:AVCN). This is a biopharmaceutical company focused on science and evidence-based delivery that has partnerships with several large hospitals such as Princess Margaret, and pharmaceutical giant Johnson & Johnson. Azadian explains Avicanna’s low-cost cultivation in Colombia and its four verticals structure in agriculture, medical, consumer and pharma. He also discusses how the company does things the right way, and why its setting gold standards as it scales up into a global leader. PLEASE SIGN UP FOR OUR FREE DAILY EMAIL, “THE MORNING NEED TORead More →

Capital Ideas Media publisher Mark Bunting sits down with Heritage Cannabis (CSE:CANN; OTC:HERTF) CEO Clint Sharples, who details the company’s plans for a seed to sale, vertically integrated operation with a focus on the increasingly popular extracts market. Sharples says Heritage wants to have annualized revenue of between $35 and $50 million by the end of 2019. This company has yet to be fully valued by investors. PLEASE SIGN UP FOR OUR FREE DAILY EMAIL, “THE MORNING NEED TO KNOW” TO HELP GET YOU READY FOR YOUR INVESTMENT DAY CAPITALIDEASMEDIA.COM FULL DISCLOSURE: NOTHING ON THIS SITE SHOULD EVER BE CONSIDERED TO BE ADVICE, RESEARCH OR ANRead More →

Capital Ideas Media publisher Mark Bunting in conversation with Morgan Good, founder, President and CEO of Delrey Metals, which is tapping demand for vanadium from the steel, energy storage, and electric vehicle sectors with its flagship property in Newfoundland and Labrador, and four properties in B.C. Good explains why vanadium is a hot commodity, and how Delrey plans to prove out the value of its properties , and attract a major buyer. PLEASE SIGN UP FOR OUR FREE DAILY EMAIL, “THE MORNING NEED TO KNOW” TO HELP GET YOU READY FOR YOUR INVESTMENT DAY CAPITALIDEASMEDIA.COM FULL DISCLOSURE: NOTHING ON THIS SITE SHOULD EVER BE CONSIDERED TORead More →

Join Capital Ideas Media publisher Mark Bunting as he talks to Aaron Dunn, Senior Analyst at KeyStone Financial. Aaron gives you six growth, dividend and U.S. top picks, and excellent insight into how KeyStone’s Canadian Small Cap Growth portfolio has an average annual return of more than 36% since 1998. PLEASE SIGN UP FOR OUR FREE DAILY EMAIL, “THE MORNING NEED TO KNOW” TO HELP GET YOU READY FOR YOUR INVESTMENT DAY CAPITALIDEASMEDIA.COM FULL DISCLOSURE: NOTHING ON THIS SITE SHOULD EVER BE CONSIDERED TO BE ADVICE, RESEARCH OR AN INVITATION TO BUY OR SELL ANY SECURITIES, PLEASE SEE MY TERMS & CONDITIONS PAGE FOR A FULL DISCLAIMER.Read More →